Adaptimmune Archives -

Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for

Roche dives further into cancer cell therapy with Adaptimmune deal

https://pharmaphorum.com/news/roche-dives-further-into-cancer-cell-therapy-with-adaptimmune-deal/

Oncology/ Slider in video/ Video/ Views & Analysis/ Views and analysis

Health Innovators – Jo Brewer, Adaptimmune

Paul Tunnah Adaptimmune, cell therapy, health innovators, immunotherapy, Innovation 0 Comment

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic

Health Innovators – Jo Brewer, Adaptimmune

https://pharmaphorum.com/video/health-innovators-jo-brewer-adaptimmune/

News/ News/ Oncology

Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapies

Richard Staines Adaptimmune, Astellas, cancer 0 Comment

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The

Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapies

https://pharmaphorum.com/news/astellas-to-work-with-adaptimmune-to-develop-off-the-shelf-t-cell-therapies/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Q&A: Adaptimmune’s Elliot Norry on cell therapy

George Underwood Adaptimmune, CAR T, cell therapy 0 Comment

Dr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing

Q&A: Adaptimmune’s Elliot Norry on cell therapy

https://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/

News/ News

Change at the top at Adaptimmune as Noble stands down

Phil Taylor Adaptimmune, immuno-oncology, Oncology, TCR 0 Comment

The long-serving CEO and founder of UK biotech Adaptimmune, James Noble, is standing down, to be replaced by

Change at the top at Adaptimmune as Noble stands down

https://pharmaphorum.com/news/change-at-the-top-at-adaptimmune-as-noble-stands-down/

Cancer/ News/ R&D/ UK & Europe

Adaptimmune and GSK’s novel T-cell therapy works in solid tumours

Andrew McConaghie Adaptimmune, cancer, CAR T, GlaxoSmithKline, R&D 0 Comment

Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round cell liposarcoma (MRCLS).

Adaptimmune and GSK’s novel T-cell therapy works in solid tumours

https://pharmaphorum.com/news/adaptimmune-gsks-novel-t-cell-therapy-works-solid-tumours/

GlaxoSmithKline/ News

GSK takes option to develop T-cell therapy with Adaptimmune

Richard Staines Adaptimmune, CAR T, Gilead, GlaxoSmithKline, Novartis 0 Comment

GlaxoSmithKline has jumped onto the T-cell cancer therapy bandwagon, taking an option with US biotech Adaptimmune to develop

GSK takes option to develop T-cell therapy with Adaptimmune

https://pharmaphorum.com/news/gsk-t-cell-therapy-adaptimmune/

Cancer/ News/ UK & Europe

Adaptimmune revives ovarian cancer trial

Richard Staines Adaptimmune, cancer, immuno-oncology, Juno, Kite, T-cell 0 Comment

T-cell trial will include controversial chemo agent fludarabine.

Adaptimmune revives ovarian cancer trial

https://pharmaphorum.com/news/adaptimmune-revives-ovarian-cancer-trial/

News/ R&D

Adaptimmune progresses T-cell therapy trial

Richard Staines Adaptimmune, cancer, synovial sarcoma, T-cell 0 Comment

Biotech says “robust” clinical response in early stage trial.

Adaptimmune progresses T-cell therapy trial

https://pharmaphorum.com/news/adaptimmune-progresses-t-cell-therapy-trial/

Trending

Adaptimmune

Login